[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-flutter\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-flutter":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,47,72,89,115,138,167,194,219,245,265,293,320,349,372,393,421,443,471,507,530,553,581,606,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100440400","baseline-atrial-fibrosis-predicts-risk-for-post-operative-atrial-fibrillation-in-patients-undergoing-cardiac-surgery-100440400",false,"NCT05014802","Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: A Pilot Study for SAPPORO-AF","Inclusion Criteria:\n\n* Male or female patients age 40 years of age or older\n* Patients with no history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) scheduled to undergo cardiac surgery (These surgeries include but are not limited to coronary artery bypass graft (CABG), valvular repair\u002Freconstruction, aneurysm repair, and insertion of pacemaker).\n\nExclusion Criteria:\n\n* Patients with a history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia)\n* Patients with a history of cardiac or open chest surgery\n* Patients with a history of catheter ablation\n* Patients under the age of 40\n* Patients with left ventricular assist device (LVAD) or scheduled to have LVAD implanted\n* Patients who have previously undergone extracorporeal membrane oxygenation (ECMO)\n* Patients who have undergone or will undergo heart transplantation\n* Patients with any health related Late Gadolinium Enhancement (LGE)-MRI contraindications (including previous allergic reaction to gadolinium, pacemakers, defibrillators, other devices\u002Fimplants contraindicated for MRI)\n* Acute or chronic severe renal disease with a low glomerular filtration rate (GFR), \\\u003C30 mL per minute per 1.73 m2 will be excluded from the trial. (A creatinine measurement should be available within the last 6 months. If not, a creatinine blood test will be drawn to assess for renal function before the MRI acquisition).\n* Patients weighing \\> 300 lbs. (MRI image quality decreases due to increased body mass index)\n* Patients currently pregnant or breastfeeding, or plan to become pregnant during the study period\n* Patients with cognitive impairment preventing them from giving informed consent will be excluded from the study\n* Patients who cannot read, speak, and\u002For understand English","ALL","40 Years","120 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","The study aims to evaluate and compare the incidence of atrial arrhythmias (including Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia) stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial wall area. The investigators hypothesize that patients with a higher baseline Utah fibrosis staging will experience a higher incidence of POAF.\n\nThe study also aims to evaluate and compare the in-hospital mortality, length-of-stay (LOS), complication rates (strokes, pneumonia, respiratory failure etc.) of the different Utah fibrosis stage cohorts. Perform cost analysis and compare between patients with POAF and patients without POAF. The investigators hypothesize that patients experiencing POAF will have a higher mortality rate, longer LOS, greater complications, and therefore, additional hospital costs.",[26,27,28,29],"Atrial Fibrillation","Atrial Arrhythmia","Atrial Flutter","Atrial Tachycardia",[31,32,33],"Atrial Fibrosis","Cardiac Magnetic Resonance Imaging","Cardiac surgery","RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2021-11-21",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"Tulane University","OTHER",3,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100613795","feasibility-study-on-the-verafeye-imaging-and-navigation-system-for-guided-catheter-ablation-procedures-100613795","NCT07271238","Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures","INSiGHT","Inclusion Criteria:\n\n* IC1: Subject is at least 18 years of age at the time of consent\n* IC2: Subject is scheduled to undergo a standard of care catheter-ablation procedure to treat AFL\u002FAF, according to current international and local guidelines and per physician discretion\n* IC3: Subject is able to understand and willing to provide written informed consent\n* IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site\n\nExclusion Criteria:\n\n* EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion\n* EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)\n* EC3: Subject implanted with an active cardiac rhythm management device (e.g. pacemaker, CRT, ICD)\n* EC4: Unrecovered\u002Funresolved Adverse Events from any previous invasive procedure\n* EC5: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure\n* EC6: Life expectancy less than 12 months\n* EC7: Current LA thrombus Note: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.\n* EC8: Subjects who are currently enrolled in another study","18 Years",{"count":21,"type":22},"INTERVENTIONAL",[58],"NA","The objective of the study is to collect data on the usability and integration of the VERAFEYE Imaging and Guidance System in adult patients indicated to undergo a standard of care catheter-based ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF).\n\nResults from this study may be used to guide development and refinement the VERAFEYE Imaging and Guidance System capabilities.",[26,28,27],"2026-06-09",{"date":63,"type":38},"2026-06-10",{"date":65,"type":38},"2026-03-03",{"date":67,"type":22},"2026-10-15",{"name":69,"class":70},"LUMA Vision Ltd.","INDUSTRY",1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":56,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":71},"100609099","anatomical-navigation-for-guided-electrophysiology-in-afl-and-afib-100609099","NCT07210151","Anatomical Navigation for Guided Electrophysiology in AFL and AFib","ANGEL-AF","Inclusion Criteria:\n\n* IC1: Subject is at least 18 years of age at the time of consent\n* IC2: Subject is scheduled to undergo a catheter-ablation procedure to treat AFL\u002FAF (\\*according to current international and local guidelines and per physician discretion)\n* IC3: Subject is able to understand and willing to provide written informed consent\n* IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site\n\nExclusion Criteria:\n\n* EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion\n* EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)\n* EC3: Unrecovered\u002Funresolved Adverse Events from any previous invasive procedure\n* EC4: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure.\n* EC5: Life expectancy less than 12 months\n* EC6: Current LA thrombus\n\nNote: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.",{"count":21,"type":22},[58],"The objective of the study is to collect data on the use of the VERAFEYE Anatomical Guidance System in adult patients indicated to undergo a catheter ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF).\n\nThe study will collect specific information on management of AFL\u002FAF ablation procedures with the commercial VERAFEYE Anatomical Guidance System including but not limited to acute procedural success , and how the VERAFEYE Anatomical Guidance System is used overall. Results from this study may be used to guide development and refinement the VERAFEYE Anatomical Guidance System.",[26,28,27],{"date":63,"type":38},{"date":85,"type":38},"2026-01-29",{"date":87,"type":22},"2026-11-01",{"name":69,"class":70},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":56,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":46},"100593131","left-atrial-imaging-prior-to-cardioversion-leveraging-computed-tomography-to-rule-out-thrombus-in-the-emergency-department-la-clotted-100593131","NCT07002450","Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)","LA CLOTTED","Inclusion Criteria:\n\n1. Age ≥18 years old; and\n2. Primary symptomatic AF without a reversible underlying cause (e.g. sepsis, pneumonia, pulmonary embolism, hyperthyroidism)\n3. LA imaging required before cardioversion according to local clinical practice guidelines\n\nExclusion Criteria:\n\n1. Patients with an indication for emergency cardioversion (e.g. hemodynamic instability (systolic blood pressure\\\u003C90mmHg or signs of shock), cardiac ischemia (ongoing severe chest pain or marked ST depression on ECG \\>2mm), or pulmonary edema (significant dyspnea, crackles, or hypoxia)); or\n2. Contraindication to CCT (renal insufficiency (eGFR\\\u003C 45ml\u002Fmin\u002F1.73m2), allergy to intravenous contrast agents, pregnancy (contraindications to radiation exposure), or inability to perform 20-second breath-hold)",{"count":97,"type":22},190,[58],"The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management.\n\nThis will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care.\n\nParticipants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.",[101,28],"Atrial Fibrillation (AF)",[103,104,105,106],"Cardiac computed tomography angiography","Cardioversion","Atrial flutter","Atrial fibrillation","2026-06-08",{"date":61,"type":38},{"date":110,"type":38},"2025-06-15",{"date":112,"type":22},"2028-06-15",{"name":114,"class":45},"Ottawa Heart Institute Research Corporation",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":56,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100383017","acute-atrial-fibrillation-and-flutter-treated-electively-100383017","NCT04267159","Acute Atrial Fibrillation and Flutter Treated Electively","Acute Atrial Fibrillation and Flutter Treated Electively - A Randomized Controlled Clinical Trial on the Safety of Elective Management of Acute Atrial Fibrillation and Flutter","AFFELECT","Inclusion Criteria:\n\n* Patients presenting with acute (\\\u003C48hours) atrial fibrillation or atrial flutter to ER\n* Planned acute rhythm control for the arrhythmia by the attending physician in ER\n* Good perceived health as assessed by attending physician in ER\n* Resting heart rate 110bpm or lower before or after adequate rate control therapy\n\nExclusion Criteria:\n\n* Haemodynamically stable (mean arterial pressure above 60mmHg)\n* Need for acute restoration of sinus rhythm due to some other somatic cause\n* No other major complicating acute illness (e.g. decompensated HF or acute MI)\n* Anticoagulation not safe\n* Mechanical heart valve or mitral stenosis\n* The need for prolonged (\\>24h) hospitalization due to any cause\n* Exceptionally high risk for thromboembolic events (e.g. history of thromboembolic stroke regardless of adequate anticoagulation)\n* Transesophageal echocardiography contraindicated",{"count":124,"type":22},500,[58],"The AFFELECT -study compares two types of treatment modalities for acute atrial fibrillation or flutter for patients in whom rhythm control is desirable. The main purpose is to observe if these arrhythmias can be safely treated electively (within 5-9 days).\n\nAll patients are recruited in the emergency department. Patients must be in good clinical condition so that they can be discharged regardless to which treatment modality is randomly selected to them. Patients randomized to conventional care are treated conventionally which means acute rhythm control is applied by electrical or medical cardioversion in the emergency department (within 48 hours of onset of the arrhythmia). Patients randomized to elective care are discharged immediately after adequate temporary rhythm control is assured.\n\nAll patients will visit a cardiologist out-patient clinic at approximately one week after the emergency room visit. Patients randomized to elective treatment and still in atrial fibrillation or in atrial flutter will be restored to sinus rhythm by electrical or medical cardioversion at the out-patient clinic. Cardiovascular status and treatment options are evaluated for all patients.\n\nAnticoagulation is managed according existing guidelines for all patients. Due to possibility of delayed cardioversion in the interventional group (elective care group), all patients receive anticoagulation before the out-patient clinic despite their thromboembolic risk. All patients who have not received adequate anticoagulation for three weeks prior to the delayed cardioversion will undergo a transesophageal cardiac ultrasound to ensure they are not in excess risk for thromboembolic events. Patients randomized to elective treatment have the possibility to opt-out and undergo acute cardioversion if their symptoms are unmanageable during the first week before the out-patient clinical.\n\nAll patients are monitored for their symptoms by a standardized quality-of-life questionnaire and for possibly required acute medical interventions during the first week and one month after the out-patient clinic. After one month, all patients undergo an electrocardiography (ECG) to ensure the maintenance of normal rhythm in both treatment groups. After the months follow-up all patients are subsequently monitored for a maximum of five years for need of medical interventions due to atrial fibrillation of atrial flutter. New antiarrhythmics such as flecainide are not prescribed during the first month.",[26,28],"2026-05-19",{"date":130,"type":38},"2026-05-22",{"date":132,"type":38},"2020-02-10",{"date":134,"type":22},"2029-06",{"name":136,"class":45},"Tampere University",4,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":71},"100636945","home-monitor-for-aa-burden-detection-iit-in-twn-100636945","NCT07572279","Home Monitor for AA Burden Detection IIT in TWN","The Clinical Follow-Up of the Amvia Pacemaker Family Using Atrial Anti-Tachycardia Pacing (aATP) and Home Monitoring Function in the Patients With Paroxysmal Atrial Fibrillation (PAF)","FF108","Inclusion Criteria:\n\n* Adult patients ≥ 20 years of age\n* Diagnosed with Paroxysmal Atrial Fibrillation (PAF) or atrial flutter who have been implanted or planned to implant with permanent pacemaker device\n* The diagnosis of AF is confirmed on a 12-lead electrocardiogram (ECG) or lasting \\>30 seconds in single lead ECG monitor\n* Implanted within 12 weeks prior to enrollment or being considered for implantation of a PPM with Home Monitoring technology\n* Able to give informed consent for the participation in the trial\n\nExclusion Criteria:\n\n* Patients are not able to use CardioMessenger 4G or its successors\n* Life expectancy \\\u003C 1 year\n* Sepsis\n* Long-standing Persistent Atrial Fibrillation or Permanent Atrial Fibrillation\n* Pregnant or breast-feeding women\n* Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints\n* Participation in another prospective interventional clinical study within a period of 4 weeks prior to the implantation of Atrial Arrhythmia\n* Present or history of drug addiction\n* Any other condition that, in the investigator's judgment, might increase the risk to the patients or affect trial quality\n* Patients underwent implantable cardioverter-defibrillator implantation","20 Years",{"count":148,"type":22},30,"Primary Endpoint:\n\n* Early detection rate in Atrial Arrhythmia (AA) burden\n* Data transmission success rate for overall number of atrial burden collection during the monitoring period\n\nSecondary Endpoints:\n\n* Atrial burden occurrence at 3\u002F6\u002F12 months post-aATP\n* Incidence of arrhythmia\n* Safety: Immediate (\\\u003C 24 hours), in-hospital, 3 months, 6 months and 12 months adverse events",[151,28],"Paroxysmal Atrial Fibrillation (PAF)",[153,154,155,156],"Paroxysmal Atrial Fibrillation","atrial flutter","permanent pacemaker device","Home Monitoring technology","NOT_YET_RECRUITING","2026-05-04",{"date":160,"type":38},"2026-05-07",{"date":162,"type":22},"2026-06-01",{"date":164,"type":22},"2030-12-31",{"name":166,"class":45},"National Taiwan University Hospital",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":56,"phases":177,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100636881","phase-4-cardiologist-administered-midazolam-vs-anaesthesiologist-assisted-propofol-sedation-for-transoesophageal-echocardiography-guided-cardioversion-of-atrial-fibrillation-100636881","NCT07571447","Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation","Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation (CARDIOZOLAM-1)","CARDIOZOLAM-1","Inclusion Criteria:\n\n* Adult patients (≥18 years) with atrial fibrillation or flutter\n* Scheduled for transoesophageal echocardiography-guided direct current cardioversion\n\nExclusion Criteria:\n\n1. Previous enrolment in the trial\n2. Expected prolonged hospitalisation (\\>8 hours) despite sinus rhythm restoration:\n\n   * Ongoing medical needs after cardioversion (e.g., decompensation or infection)\n   * Planned procedures after cardioversion (same-day TTE or pacemaker test allowed)\n   * Social barriers for same-day discharge\n3. Indication for anaesthesiology assistance:\n\n   * Haemodynamic instability (systolic blood pressure \\\u003C90 mmHg)\n   * Known severe pulmonary disease (FVC or FEV1 \\\u003C50% predicted)\n   * Body mass index \\>40 kg\u002Fm2\n   * Previous complications or allergic reactions to sedation\n4. Contraindications:\n\n   * Pregnant or breastfeeding\n   * Intracardiac thrombus\n   * Total benzodiazepine dose used for TOE \\>20 mg\n\nAbbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.",{"count":176,"type":22},220,[178],"PHASE4","Irregular heart rhythms, known as atrial fibrillation or atrial flutter, are common conditions that can increase the risk of stroke and heart failure. A standard treatment to restore a normal rhythm is a controlled electric shock, known as cardioversion. However, if the irregular rhythm has lasted more than 24 hours, if the duration is uncertain, and if the patient has not been on blood-thinning medication for at least three weeks, doctors must first check for blood clots in the heart. This is done using a special ultrasound scan of the heart through the food pipe.\n\nBoth the scan and the electric shock treatment require sedation to make the patient relaxed or asleep. The scan uses mild sedation from a cardiologist, while the shock needs a stronger sedative given by an anaesthesiologist. But needing this extra doctor can cause delays, so patients often wait longer for treatment and to go home.\n\nThis study will test whether a cardiologist can safely handle both steps using a sedative called midazolam. This study will include 220 adults at multiple hospitals in Denmark and compare this new approach to standard care. Researchers will track how quickly patients go home, how well the treatment works, any serious side effects, what patients think about the experience, and how much money can be saved.\n\nIf proven safe and effective, this new method could reduce treatment delays, shorten hospital stays, and lower healthcare costs-ultimately improving care for patients and making the healthcare system more efficient.",[101,28],[182,183],"Direct current cardioversion","Transoesophageal echocardiography","2026-04-30",{"date":186,"type":38},"2026-05-06",{"date":188,"type":22},"2026-05",{"date":190,"type":22},"2027-05",{"name":192,"class":45},"Gødstrup Hospital",2,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":23,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":71},"100631485","heartbeam-ecg-registry-100631485","NCT07501299","HeartBeam ECG Registry","Collection of ECG Recordings Using the HeartBeam 3-Lead ECG Recorder","Inclusion Criteria:\n\nUndergoing ECG as part of standard of care Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nOpen chest wounds or surgery to the chest or abdomen within 30 days Inability to complete ECG acquisition with either HeartBeam device or standard 12-L ECG Unstable condition where registry participation may interfere with care",true,{"count":203,"type":22},600,"1 Day","The HeartBeam ECG Registry will collect ECG recordings acquired with the HeartBeam System with relevant clinical information in clinical settings.",[26,28,207,208,209],"Bradycardia","Tachycardia","Arrhythmia","2026-03-24",{"date":212,"type":38},"2026-03-30",{"date":214,"type":22},"2026-03",{"date":216,"type":22},"2028-12",{"name":218,"class":70},"HeartBeam, Inc.",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":56,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":71},"100627335","efficacy-of-early-rhythm-control-therapy-in-patients-with-subclinical-atrial-fibrillation-100627335","NCT07447297","Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation","SubclincalAF","Inclusion Criteria:\n\n* Among patients with Cardiac implantable electronic device (CIED), subjects with atrial high rate episodes found Cardiac implantable electronic devices: implantable loop recorder, pacemaker, implantable cardioverter defibrillator(ICD), cardiac resynchronized therapy(CRT)\n* Patients aged 19 or older who have agreed to the study (if voluntary consent is deemed difficult, consent from legal representatives is obtained together)\n* If the accumulated period of the atrial high rate episode during the three-month observation period is more than 21 hours\n* Patients whose atrial fibrillation has not been confirmed by electrocardiogram or holter monitoring within the past year from the time atrial high rate episode was detected\n\nHowever, enrollment is possible even if it includes one of the following two cases ⓐ Patients diagnosed and recorded as atrial fibrillation on medical records but not confirmed by electrocardiogram or holter monitoring\n\nⓑ If there is a record of atrial fibrillation, but Paroxysmal AF less than 30 seconds\n\nExclusion Criteria:\n\n* Patients deemed inappropriate to participate in the study by the investigator\n* Patients diagnosed with atrial fibrillation with 12-lead electrocardiogram or holter within the past year prior to participation in the study\n* Patients taking Class Ic, III of antiarrhythmic drugs prior to study participation\n* Patients who have had rhythm control treatments such as Radiofequency catheter ablation (RFCA), Total thoracoscopic ablation (TTA), Maze procedure (MAZEop), and antiarrhythmic treatment due to atrial fibrillation (except for CTI ablation with AFL)\n* Patients whose life expectancy is less than one year (e.g., patients who can't even have a heart transplant, patients who receive DNR, Patients in hospice wards who refuse life-sustaining treatment, terminal cancer patients who cannot receive radiation or chemotherapy, etc.)","19 Years",{"count":228,"type":22},520,[58],"The goal of this study to find out the efficacy of early rhythm therapy in patients with subclinical atrial fibrillation detected by Cardiac Electronic Implantable Devices.\n\nEarly rhythm therapy includes antiarrhythmic drug, cardioversion, and catheter ablation. The general control group receives general management without the above atrial fibrillation rhythm control treatment.\n\nResearchers will compare early rhythm control groups to general control groups to see if early rhythm therapy works to reduce the atrial fibrillation burden by 50% or more, or decrease the incidence of clinical AF documentation.\n\nParticipants will:\n\n* Randomly allocated to two groups at a 1:1 ratio.\n* Receive the treatment according to their assigned group.\n* Visit the clinic once every three months for checkups and tests.",[101,232,28],"Diseases of the Circulatory System",[234,235,236],"earl rhythm control","subclinical atrial fibrillation","antiarrhythmic drugs","2026-02-27",{"date":65,"type":38},{"date":240,"type":38},"2024-01-02",{"date":242,"type":22},"2029-12-31",{"name":244,"class":45},"Samsung Medical Center",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":71},"100620142","intracardiac-echocardiography-guided-cavotricuspid-isthmus-ablation-with-a-circular-shaped-pulsed-field-ablation-catheter-100620142","NCT07353775","Intracardiac Echocardiography-Guided Cavotricuspid Isthmus Ablation With a Circular-Shaped Pulsed Field Ablation Catheter","Intracardiac Echocardiography-Guided Cavotricuspid Isthmus Ablation With a Circular-Shaped Pulsed Field Ablation Catheter: A Prospective Study on Effectiveness and Safety","Inclusion Criteria:\n\n* Paroxysmal or persistent atrial fibrillation\n* Aged 18 years or older\n* Scheduled for CTI ablation\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Previous CTI ablation\n* Significant congenital heart disease or structural anomaly affecting the CTI\n* Active intracardiac thrombus\n* Pregnancy or lactation\n* Severe renal\u002Fhepatic insufficiency\n* Active systemic infection or sepsis\n* Life expectancy of less than 12 months\n* Unable to provide written informed consent.",{"count":253,"type":22},150,"This observational study aims to evaluate the effectiveness and safety of a circular-shaped pulsed field ablation (PFA) catheter for CTI ablation under the guidance of intracardiac echocardiography (ICE). The main question it aims to answer is:\n\nIs the circular-shaped PFA catheter an effective and safe tool for achieving acute success for CTI ablation? Patients undergoing CTI ablation with a circular-shaped PFA catheter will be prospectively enrolled.",[101,28],"2026-01-18",{"date":258,"type":38},"2026-01-20",{"date":260,"type":38},"2025-01-15",{"date":262,"type":22},"2026-03-15",{"name":264,"class":45},"Beijing Anzhen Hospital",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":271,"targetDuration":273,"studyType":23,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100609302","detection-of-atrial-fibrillation-through-voice-signal-processing-100609302","NCT07212816","Detection of Atrial Fibrillation Through Voice Signal Processing","Inclusion Criteria:\n\nTo participate in this study, patients must meet all of the following inclusion criteria:\n\n1. Diagnosis of atrial fibrillation and presenting for cardioversion at Allina Health in atrial fibrillation\n2. 3\\. ≥ 18 years of age Written informed consent obtained from patient in English\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria must be excluded from this study:\n\n1. History of a pacemaker\n2. History of dysphasia or difficulty with word finding\n3. History of vocal cord dysfunction\n4. Patient with atrial flutter as presenting arrhythmia\n5. Planned transesophageal echocardiogram (TEE) with cardioversion",{"count":272,"type":22},40,"1 Month","This study is testing a new technology that listens to a person's voice during short phone calls to help identify heart rhythm problems. The goal is to see if voice signal analysis can tell the difference between a normal rhythm (sinus rhythm) and an irregular rhythm (atrial fibrillation).\n\nWe are enrolling adults scheduled for a standard heart procedure called cardioversion, which is used to reset the heart to a normal rhythm. Each participant will provide voice recordings through three short phone calls: before cardioversion, just after the procedure, and at a follow-up visit. Results will be compared with standard heart rhythm tests (electrocardiograms or ECGs).\n\nThis research may lead to a simple, low-cost way to monitor heart rhythms remotely without requiring special devices.",[101,28],[104,277,209,26,278,279,280,281,282,283],"Irregular Heart Rhythm","Afib","Artificial Intelligence (AI) in Cardiology","Digital Biomarkers","Voice Biomarkers","Voice Signal Processing","Voice based monitoring","2025-10-01",{"date":286,"type":38},"2025-10-08",{"date":288,"type":22},"2025-10-15",{"date":290,"type":22},"2025-11-30",{"name":292,"class":45},"Vital Audio Inc",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":300,"targetDuration":302,"studyType":23,"phases":4,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":71},"100608024","electrophysiological-registry-duesseldorf-100608024","NCT07196176","Electrophysiological Registry Duesseldorf","Registry on Electrophysiological Studies (EPS) at University Hospital Düsseldorf","Inclusion Criteria:\n\n* Patients who undergo an electrophysiological study (EPS) or electrical cardioversion at University Hospital Düsseldorf since 2015 (retrospective cohort)\n* Patients scheduled to undergo an EPS or electrical cardioversion at University Hospital Düsseldorf from 2019 onward (prospective cohort) •- Written informed consent for participation in the registry (prospective part only)\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Lack of written informed consent\n* Pregnancy",{"count":301,"type":22},1000,"2 Years","This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.",[101,28,305,306],"Supraventricular Tachycardias","Ventricular Tachycardia (VT)",[308,309,310],"atrial fibrillation","catheter ablation","cardioversion","2025-09-26",{"date":313,"type":38},"2025-09-29",{"date":315,"type":38},"2019-06-01",{"date":317,"type":22},"2031-12-31",{"name":319,"class":45},"Heinrich-Heine University, Duesseldorf",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":56,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100385439","comparison-of-laa-closure-vs-oral-anticoagulation-in-patients-with-nvaf-and-status-post-intracranial-bleeding-100385439","NCT04298723","Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.","Randomized Comparison of Interventional Closure of the Left Atrial Appendage Using a LAA Closure Device Versus Oral Anticoagulation Therapy in Patients With Non-valvular Atrial Fibrillation and Status Post Intracranial Bleeding.","CLEARANCE","Inclusion Criteria:\n\n* Signed written informed consent\n* Documented atrial fibrillation (paroxysmal, persistent, long-standing persistent or permanent)\n* CHA2DS2VASc-Score ≥2\n* Status post intracranial bleeding \\>6 weeks\n* Favorable LAA anatomy\n* Subject eligible for a LAA occluder device\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Comorbidities other than AF requiring chronic (N)OAC therapy, e.g. mechanical heart valve prosthesis, hereditary thrombophilia requiring livelong OAC - recurrent thrombosis\n* Symptomatic carotid disease (if not treated)\n* Thrombus in the left atrium or left atrial appendage\n* Active infection or active endocarditis or other infections resulting in bacteremia\n* Functional Impairment (modified ranking scale ≥4 )\n* Severe liver failure (Child-Pugh class C or liver failure with coagulopathy)\n* Pregnancy or breastfeeding\n* Subject with participation in another interventional clinical trial during this study or within 30 days before entry into this trial.\n* Known terminating disease with life expectancy \\\u003C1 year (including those with end-stage heart failure)\n* Subjects, who are committed to an institution due to binding official or court order\n* Subjects with planned cardiac or non-cardiac surgery or intervention. (These subjects can be included 30 days after intervention \u002F surgery",{"count":329,"type":22},530,[58],"Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, there is a risk that clots can form in the heart, especially in the left atrium. If these clots come loose, there is a risk of stroke. To prevent strokes, patients with atrial fibrillation and status post ICB can be treated with anticoagulants. This medication therapy prevents blood clots from forming in the heart, but can also cause bleeding. Another therapy option is the occlusion of the left atrium. After closure of the left atrium, only a short anticoagulation therapy is necessary until the occluder has healed. The aim of the study is to compare these two treatment approaches. In this study only already approved drugs and occlusion systems will be used.",[333,101,28],"Intracranial Hemorrhages",[335,336,26,337,338],"Intracranial Hemorrhage","Intracranial Bleeding","Anticoagulation","LAA Occlusion","2025-08-25",{"date":341,"type":38},"2025-09-02",{"date":343,"type":38},"2020-06-16",{"date":345,"type":22},"2029-12",{"name":347,"class":45},"Jena University Hospital",33,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":56,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":71},"100602438","beta-blockers-for-prevention-of-supraventricular-arrhythmia-following-pfo-closure-100602438","NCT07123506","Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure","BRAVE PFO","Inclusion Criteria:\n\n1. Age 19 years or older\n2. Patients scheduled to undergo Patent Foramen Ovale closure using the Cocoon Patent Foramen Ovale Occluder\n3. Individuals who have provided informed consent for study participation\n\nExclusion Criteria:\n\n1. History of paroxysmal, persistent, or permanent atrial arrhythmia\n2. Atrial arrhythmia confirmed by a 14-day Holter ECG using the AT Patch before PFO closure\n3. Patients with uncontrolled asthma or chronic obstructive pulmonary disease (COPD)\n4. Patients with high-degree atrioventricular (AV) block\n5. History of heart failure, severe valvular disease, or left ventricular dysfunction (ejection fraction \\\u003C50%)\n6. Patients for whom initiating or discontinuing beta-blocker therapy is deemed impossible by the investigator\n7. Patients who, as assessed by the investigator, cannot be followed up for one year after enrollment\n8. Patients with hypersensitivity or contraindications to any proposed drug therapy or device component\n9. Patients with an expected life expectancy of less than one year\n10. Patients currently participating in another investigational drug or device study",{"count":357,"type":22},350,[58],"\"The primary objective of the study is to evaluate whether the incidence of symptomatic or asymptomatic atrial fibrillation, atrial flutter, and atrial tachycardia within 30 days after percutaneous closure of idiopathic patent foramen ovale is reduced in the beta-blocker treatment group compared to the non-treatment group.\n\nThe secondary objective is to assess the safety and performance of the Cocoon Patent Foramen Ovale Occluder and collect real-world data on patient outcomes.\n\nPatients will be randomly assigned in a 1:1 ratio to either the beta-blocker treatment group or the non-treatment group. Randomization will be performed using a 1:1 allocation ratio with stratification based on (1) PFO device size and (2) sex, employing a block randomization method (mixed block sizes of 4 or 6). This process will be conducted independently through an interactive web response system.\n\nThe beta-blockers used in this study are extended-release beta-blockers, specifically bisoprolol or nebivolol. The choice between bisoprolol and nebivolol will be determined at the discretion of the investigators, with the initial dose set at the minimum dose for each drug (1.25 mg once daily). During the study period, adjustments to the beta-blocker dose, including maintenance or modification, will be made based on the investigators' clinical judgment, taking into account the patient's heart rate, blood pressure, and medication adherence. All reasons for dose adjustments will be documented in detail.\"",[26,28,361,362],"Tachycardia, Supraventricular","Heart Septal Defects, Atrial","2025-08-07",{"date":365,"type":38},"2025-08-14",{"date":367,"type":22},"2025-09",{"date":369,"type":22},"2029-05-03",{"name":371,"class":45},"Yonsei University",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":379,"targetDuration":380,"studyType":23,"phases":4,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":71},"100601334","registry-of-atrial-arrhythmia-ablation-procedures-using-pulsed-field-ablation-in-poland-100601334","NCT07109141","Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","PFA Registry","Inclusion Criteria:\n\n* Informed consent obtained from the participant\n* Subject is undergoing ablation of an atrial arrhythmia using the PFA\n\nExclusion Criteria:\n\n\\-",{"count":124,"type":22},"12 Months","The aim of the described project is to establish a multicenter, nationwide registry of atrial arrhythmia ablation procedures using the Pulsed Field Ablation (PFA) method. These procedures have only recently begun to be performed in several centers across Poland. With proper coordination of the registry, this will enable the consolidation of clinical data and the expansion of knowledge regarding the efficacy and safety of these procedures.",[101,28,29,383,384],"Ablation Techniques","Pulsed Field Ablation","2025-07-31",{"date":363,"type":38},{"date":388,"type":38},"2024-08-01",{"date":390,"type":22},"2030-07-01",{"name":392,"class":45},"Wroclaw Medical University",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":56,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":137},"100553480","pericardiotomy-in-cardiac-surgery-100553480","NCT06486636","Pericardiotomy in Cardiac Surgery","Pericardiotomy in Cardiac Surgery Trial","PRINCE","Inclusion Criteria:\n\n* Patients greater than or equal to 18 years of age\n* Requiring surgical intervention on the proximal aorta, cardiac valves, and\u002For coronary arteries\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation or flutter\n* Cardiac surgery procedures not included in the inclusion criteria (planned ventricular assistance device, aortic arch, transplantation surgery)\n* Prior cardiac surgery requiring opening of the pericardium\n* Previous surgical instrumentation of the left pleural cavity\n* Patient undergoing minimally invasive cardiac surgery",{"count":402,"type":22},1400,[58],"PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.",[26,28,406],"Cardiac Events",[408,409,410,411],"Pericardiotomy","Cardiac Surgery","Hospital Readmission","Post-Operative Atrial Fibrillation","2025-07-09",{"date":414,"type":38},"2025-07-14",{"date":416,"type":38},"2024-10-21",{"date":418,"type":22},"2031-09-01",{"name":420,"class":45},"Population Health Research Institute",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":56,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":193},"100478547","anteroposterior-versus-anterolateral-electrode-position-for-electrical-cardioversion-of-atrial-fibrillation-100478547","NCT05511389","Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation","A Randomized Controlled Trial of Anterior-posterior Versus Anterior-lateral Shock Vectors for Electrical Cardioversion of Atrial Fibrillation","SHOCK-VECTOR","Inclusion Criteria:\n\nConsenting adult patients scheduled for non-emergent electrical cardioversion of Atrial Fibrillation or Flutter\n\nExclusion Criteria:\n\n1. Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echocardiography to rule out left atrial thrombus\n2. Anatomic contraindication to anterolateral or anteroposterior placement (e.g. skin conditions or wounds)",{"count":430,"type":22},1500,[58],"Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year.\n\nWe believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk.\n\nElectrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is \"shocked\" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial.\n\nThis study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation.\n\nWe will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal.\n\nWe hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.",[26,28],"2025-05-08",{"date":436,"type":38},"2025-05-14",{"date":438,"type":38},"2023-02-22",{"date":440,"type":22},"2027-07",{"name":442,"class":45},"McMaster University",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":56,"phases":450,"briefSummary":451,"conditions":452,"keywords":456,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100590589","empiric-pulsed-field-pulmonary-vein-isolation-during-atrial-tachycardia-ablation-in-adults-with-congenital-heart-disease-100590589","NCT06969378","Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n* Adult patients (\\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\\>30 seconds) AT\n\nExclusion Criteria:\n\n* History of sustained AF and\u002For previous catheter or surgical pulmonary vein isolation.",{"count":148,"type":22},[58],"This is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (PVI) using pulsed field ablation (PFA) in adult patients with congenital heart disease (CHD) who are presenting for atrial tachycardia (AT) ablation.",[26,29,28,453,454,384,455],"Congenital Heart Disease","Pulmonary Vein Isolation","Catheter Ablation",[308,457,154,458,459,460,461,309],"atrial tachycardia","pulsed field ablation","congenital heart disease","adult congenital heart disease","pulmonary vein isolation","2025-05-05",{"date":464,"type":38},"2025-05-13",{"date":466,"type":22},"2025-07-01",{"date":468,"type":22},"2026-06-30",{"name":470,"class":45},"Boston Children's Hospital",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":201,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":479,"targetDuration":481,"studyType":23,"phases":4,"briefSummary":482,"conditions":483,"keywords":493,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":71},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",{"count":480,"type":22},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[484,26,28,485,29,486,487,488,489,490,491,492],"Arrhythmias, Cardiac","Ventricular Tachycardia","Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Supraventricular Tachycardia","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[455,494,495,496,497,498,492],"Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":501,"type":38},"2025-03-30",{"date":503,"type":38},"2021-03-17",{"date":317,"type":22},{"name":506,"class":45},"Universitätsklinikum Hamburg-Eppendorf",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":201,"sex":17,"minAge":54,"maxAge":515,"enrollmentInfo":516,"targetDuration":518,"studyType":23,"phases":4,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":71},"100534927","get-with-the-guidelines-atrial-fibrillation-registry-100534927","NCT06245187","Get With the Guidelines Atrial Fibrillation Registry","Get With the Guidelines-Atrial Fibrillation","GWTG-AF","Inclusion Criteria:\n\n* Patients hospitalized with nonvalvular Atrial Fibrillation or Atrial Flutter\n\nExclusion Criteria:\n\n* Patients who do not have nonvalvular Atrial Fibrillation or Atrial Flutter\n* Patients under 18 years of age\n* Patients not admitted as inpatients.\n* Patients on comfort care only\n* Patients discharged to hospice.","125 Years",{"count":517,"type":22},17198,"3 Days","Get With The Guidelines-Atrial Fibrillation is designed to assist hospital care teams in consistently providing the latest evidence-based treatment for their AFib patients. At the same time, it offers a means of monitoring the quality of AFib care in U.S. hospitals and building a database for continued research and further quality improvement.",[26,28],"2025-01-27",{"date":523,"type":38},"2025-01-29",{"date":525,"type":4},"2013-01",{"date":527,"type":22},"2040-01",{"name":529,"class":45},"American Heart Association",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":552},"100556027","detection-of-perioperative-atrial-fibrillation-after-noncardiac-surgery-100556027","NCT06519747","DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery","Enhanced DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery with Continuous Electrocardiographic Monitoring","DETECT-POAF","Inclusion Criteria:\n\n1. Had undergone noncardiac surgery within the past 72 hours and requiring, or expected to require, at least one of the following:\n\n   * an overnight hospital admission after surgery\n   * day surgery that would result in a large enough physiological insult to be able to cause POAF. Procedures excluded include those that are conducted using local anesthesia alone, are less than 30 minutes in duration, and\u002For are judged to be of low physiologic insult by the local investigator.\n2. Have one of the following high-risk criteria;\n\n   * age 55-64 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥3, or an elevated postoperative troponin level;\n   * age 65-74 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥2, or an elevated postoperative troponin level; or\n   * age ≥75 years;\n3. Provide written informed consent to participate.\n\nExclusion Criteria:\n\n1. History of documented chronic (i.e., non-transient) AF before noncardiac surgery;\n2. Need for long-term systemic anticoagulation;\n3. Ongoing need for long-term dual antiplatelet treatment;\n4. Contraindication to oral anticoagulation;\n5. Severe renal insufficiency;\n6. Severe liver cirrhosis;\n7. Acute stroke in the past 14 days;\n8. Underwent cardiac surgery in the past 35 days;\n9. History of nontraumatic intracranial, intraocular, or spinal bleeding;\n10. Hemorrhagic disorder or bleeding diathesis;\n11. Known life expectancy \\\u003C1 year due to concomitant disease;\n12. Women who are pregnant, breastfeeding, or of childbearing potential not taking effective contraception;\n13. Expected to be non-compliant with follow-up and\u002For device use;\n14. Known contact allergy to monitoring device and\u002For its peripheral components;\n15. Previously enrolled in DETECT-POAF.",{"count":539,"type":22},750,"This is a multicentre prospective cohort study where patients will receive up to 14 days of continuous ECG monitoring by wearing a portable monitoring device, starting within 72 hours after noncardiac surgery.",[26,28],[543],"Cardiac monitoring","2024-11-05",{"date":546,"type":38},"2024-11-07",{"date":548,"type":38},"2024-10-15",{"date":550,"type":22},"2026-12-31",{"name":420,"class":45},6,{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":226,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":56,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":4},"100558048","analysis-of-the-efficacy-and-stability-of-a-wearable-ecg-monitor-100558048","NCT06546046","Analysis of the Efficacy and Stability of a Wearable ECG Monitor","Analysis of the Efficacy and Stability of a Single-Channel Patch-Type Wearable Electrocardiogram Monitor","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Patients admitted to Chonnam National University Hospital who require ECG monitoring\n3. Individuals who have expressed their intention to participate in this study or have obtained written consent from a proxy\n\nExclusion Criteria:\n\n1. Individuals who are unable to provide consent themselves or through a legally designated representative\n2. Individuals deemed unsuitable for participation in the clinical trial based on the researcher's judgment",{"count":561,"type":22},100,[58],"This study aims to analyze the efficacy and safety of wearable electrocardiogram (ECG) monitoring by simultaneously attaching a single-channel patch-type wearable ECG monitoring device (HiCardi+ by Mezoo Co., Ltd.) and a telemetry device (IntelliVue MX40 by Philips) used in actual wards to patients prescribed with ECG monitoring",[484,207,208,26,28,565],"Ventricular Premature Complexes",[567,568,569,570,571,572],"Monitoring","Telemetry","Wearable device","Arrhythmia alarm","Signal loss","Satisfaction survey","2024-08-11",{"date":575,"type":38},"2024-08-14",{"date":577,"type":22},"2024-09-09",{"date":501,"type":22},{"name":580,"class":45},"Mezoo Co., Ltd.",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":201,"sex":17,"minAge":54,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":56,"phases":590,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":605},"100551495","a-comparative-study-evaluating-the-vein-of-marshall-ethanol-infusion-ablation-using-an-over-the-wire-otw-balloon-versus-a-microcatheter-in-patients-with-atrial-fibrillation-100551495","NCT06460831","A Comparative Study Evaluating the Vein of MArshall Ethanol Infusion Ablation Using an Over-the-wire (OTW) Balloon Versus a microcatHeter in Patients With Atrial Fibrillation","Inclusion Criteria:\n\n1. Age range: 18-80 years.\n2. Persistent atrial fibrillation or atrial flutter dependent on the mitral isthmus.\n3. Inadequate response to antiarrhythmic drug therapy, or intolerance to antiarrhythmic drugs.\n4. New York Heart Association functional class ≤ IV,with left ventricular ejection fraction (LVEF) ≥ 35%\n\nExclusion Criteria:\n\n1. Patients with known allergies to alcohol.\n2. Participants with a history of serious cardiovascular events such as myocardial infarction or stroke within the past three months will be excluded from the study","80 Years",{"count":589,"type":22},800,[58],"The goal of this study is to compare OTW balloon with microcatheter in the Marshall vein alcohol ablation study. The main questions it aims to answer are: • Is there a difference in the effectiveness and safety of OTW balloon and microcatheter in Marshall vein alcohol ablation? Participants will be asked to:\n\nUndergo treatment with OTW balloon Undergo treatment with microcatheter If there is a comparison group: Researchers will compare the OTW balloon group and the microcatheter group to see different effects.",[26,28],[594,595],"marshall vein","mitral valve isthmus line","2024-06-13",{"date":598,"type":38},"2024-06-14",{"date":600,"type":22},"2024-06-15",{"date":602,"type":22},"2024-12-31",{"name":604,"class":45},"Shanghai Chest Hospital",5,{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":201,"sex":17,"minAge":614,"maxAge":615,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":618,"conditions":619,"keywords":624,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":71},"100408057","excessive-supraventricular-activity-and-atrial-fibrillation-100408057","NCT04593498","Excessive Supraventricular Activity and Atrial Fibrillation","Detection of Atrial Fibrillation in Patients With Excessive Supraventricular Activity","ESA-AF","Inclusion Criteria:\n\nPatients with at least 30 supraventricular extra systole (SVES)\u002Fh or a supraventricular run of at least 20 beats on a Holter recording.\n\nExclusion Criteria:\n\nAge \\\u003C 70 years, \\>89 years Atrial fibrillation \u002F flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease","70 Years","89 Years",{"count":617,"type":22},250,"The aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (ESVEA) on Holter recording should be subjected to prolonged screening with Event loop recorder in order to detect previously undiagnosed Atrial fibrillation \u002F flutter. Other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in ESVEA and control group as well as progression of atrial cardiomyopathy in ESVEA patients.",[26,28,620,621,622,623],"Supraventricular Beat, Premature","Premature Supraventricular Beats","Premature Atrial Complex","Extrasystole, Atrial",[625],"Excessive supraventricular ectopic activity","2024-03-05",{"date":628,"type":38},"2024-03-06",{"date":630,"type":38},"2022-11-01",{"date":632,"type":22},"2028-02-15",{"name":634,"class":45},"Karolinska Institutet",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":56,"phases":645,"briefSummary":646,"conditions":647,"keywords":657,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":678},"100396044","phase-4-what-is-the-optimal-antithrombotic-strategy-in-patients-with-atrial-fibrillation-undergoing-pci-100396044","NCT04436978","What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Having Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention?","WOEST-3","Inclusion Criteria:\n\n1. Patients ≥ 18 years\n2. Undergoing successful PCI (either ACS or elective PCI)\n3. History of or newly diagnosed (\\\u003C72 hours after PCI\u002FACS) atrial fibrillation or flutter with a long-term (≥ 1 year) indication for OAC\n\nExclusion Criteria:\n\n1. Contra indication to edoxaban, aspirin or all P2Y12 inhibitors\n2. Current indication for OAC besides atrial fibrillation\u002Fflutter (e.g. venous thromboembolism)\n3. \\\u003C12 months after any stroke\n4. CHADSVASc score ≥7\n5. Moderate to severe mitral valve stenosis (AVA ≤1.5 cm2)\n6. Mechanical heart valve prosthesis\n7. Intracardiac thrombus or apical aneurysm requiring OAC\n8. Poor LV function (LVEF \\\u003C30%) with proven slow-flow\n9. History of intracranial haemorrhage\n10. Active bleeding on randomization\n11. History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding, unless the causative factor has been permanently resolved\n12. Recent (\\\u003C1 month) gastrointestinal haemorrhage, unless the causative factor has been permanently resolved.\n13. Known coagulopathy\n14. Severe anaemia requiring blood transfusion or thrombocytopenia \\\u003C50 × 109\u002FL\n15. BMI \\>40 or bariatric surgery\n16. Kidney failure (eGFR \\\u003C15)\n17. Active liver disease (ALT, ASP, AP \\>3x ULN or active hepatitis A, B or C)\n18. Active malignancy excluding non-melanoma skin cancer\n19. Life expectancy \\\u003C1 year\n20. Pregnancy or breast-feeding women",{"count":644,"type":22},2000,[178],"The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown. AF patients are treated with oral anticoagulation (OAC) to prevent ischemic stroke and systemic embolism and patients undergoing percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy (DAPT), i.e. aspirin plus P2Y12 inhibitor, to prevent stent thrombosis (ST) and myocardial infarction (MI). Patients with AF undergoing PCI were traditionally treated with triple antithrombotic therapy (TAT, i.e. OAC plus aspirin and P2Y12 inhibitor) to prevent ischemic complications. However, TAT doubles or even triples the risk of major bleeding complications. More recently, several clinical studies demonstrated that omitting aspirin, a strategy known as dual antithrombotic therapy (DAT) is safer compared to TAT with comparable efficacy.\n\nHowever, pooled evidence from recent meta-analyses suggests that patients treated with DAT are at increased risk of MI and ST. Insights from the AUGUSTUS trial showed that aspirin added to OAC and clopidogrel for 30 days, but not thereafter, resulted in fewer severe ischemic events. This finding emphasizes the relevance of early aspirin administration on ischemic benefit, also reflected in the current ESC guideline. However, because we consider the bleeding risk of TAT unacceptably high, we propose to use a short course of DAPT (omitting OAC for 1 month). There is evidence from the BRIDGE study that a short period of omitting OAC is safe in patients with AF. In this study, these patients are treated with DAPT, which also prevents stroke, albeit not as effective as OAC. This temporary interruption of OAC will allow aspirin treatment in the first month post-PCI where the risk of both bleeding and stent thrombosis is greatest.\n\nThe WOEST 3 trial is a multicentre, open-label, randomised controlled trial investigating the safety and efficacy of one month DAPT compared to guideline-directed therapy consisting of OAC and P2Y12 inhibitor combined with aspirin up to 30 days. We hypothesise that the use of short course DAPT is superior in bleeding and non-inferior in preventing ischemic events. The primary safety endpoint is major or clinically relevant non-major bleeding as defined by the ISTH at 6 weeks after PCI. The primary efficacy endpoint is a composite of all-cause death, myocardial infarction, stroke, systemic embolism, or stent thrombosis at 6 weeks after PCI.",[648,649,26,28,650,651,652,653,654,655,656],"Acute Coronary Syndrome","Myocardial Infarction","STEMI - ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation MI","Bleeding","Stroke","Stent Thrombosis","Embolism","Coronary Artery Disease",[648,649,26,28,650,651,658,659,660,661,662,663,664,652,665,653,654,666,667,668],"Oral Anticoagulant","NOAC - Novel Oral Anticoagulant","DOAC - Direct Oral Anticoagulant","DAPT - Dual Antiplatelet Therapy","Antithrombotic Therapy","Dual Therapy","Triple Therapy","Thrombosis","Systemic Embolism","Percutaneous coronary intervention","Coronary artery disease","2023-12-14",{"date":671,"type":38},"2023-12-15",{"date":673,"type":38},"2023-01-11",{"date":675,"type":22},"2027-12-01",{"name":677,"class":45},"St. Antonius Hospital",20]